MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Sarepta Therapeutics Total Non Current Liabilities 2011-2025 | SRPT
Annual Total Non Current Liabilities Sarepta Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 740 M | 436 M | 430 M | 12 M | 21.1 M | 10.5 M | 8.41 M | 2.43 M | 2.75 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 740 M | 2.43 M | 185 M |
Quarterly Total Non Current Liabilities Sarepta Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.8 M | 757 K | 755 K | 760 K | 758 K | 760 K | 760 K | 993 K | 993 K | 993 K | 993 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.8 M | 755 K | 1.21 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
5 M | $ 0.55 | -10.23 % | $ 152 K |  USA |
 |
Aclaris Therapeutics
ACRS
|
5.95 M | $ 3.03 | -0.17 % | $ 234 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.09 | -2.68 % | $ 7.43 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.79 | 7.19 % | $ 457 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 1.18 | 3.07 % | $ 6.43 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 208.29 | -0.33 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
BioVie
BIVI
|
62.5 K | $ 1.2 | -0.77 % | $ 1.77 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 0.19 | -12.16 % | $ 413 M |  Israel |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 94.51 | -0.01 % | $ 27.2 B | Germany |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 12.02 | -2.67 % | $ 791 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 27.09 | -0.11 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 9.53 | -0.21 % | $ 140 M | USA |
 |
Certara
CERT
|
482 M | $ 8.86 | -0.39 % | $ 1.42 B | USA |
 |
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 4.93 | 3.79 % | $ 116 M | France |
 |
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
107 M | $ 581.66 | -0.37 % | $ 44.1 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.45 | - | $ 15.4 M | USA |
 |
AstraZeneca PLC
AZN
|
30.8 B | $ 92.77 | -0.14 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
5.46 M | - | -0.88 % | $ 598 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 26.14 | -1.0 % | $ 1.68 M | USA |